SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.

9055Background: Despite the development of targeted therapies for advanced NSCLC harboring EGFR mutations (EGFR+), acquired resistance remains inevitable. Immune checkpoint inhibitor as monotherapy...